Industry Insights · Brain–Computer Interface
May 2026: a wave of BCI funding starts betting on 'system engineering'
In May 2026, China's brain-computer interface space heated up again, with several rounds closing within half a month. Read together, the bets are clear: what decides industrialization is no longer the algorithm alone, but front-end hardware and system engineering.
Four rounds in half a month
Through early-to-mid May 2026, China's BCI funding cadence accelerated noticeably, with several deals closing within two weeks across invasive, non-invasive and brain-spine routes:
- Ruiyi Xulian: ~RMB 100M Pre-A, advancing implantable bidirectional BCI and a 'brain-spine interface';
- Naosi Technology: a >US$10M angel series, funding product engineering, neural foundation models and GMP manufacturing;
- Nanoloop: a tens-of-millions seed+ round, entering non-invasive BCI wearables for movement;
- Nuanxinjia: RMB 300M strategic financing, continuing visual-BCI clinical trials and core-technology iteration.
Competition moves from 'algorithm decoding' to system engineering
Outsiders used to put all the attention on the algorithm: can it recognize intent, can it translate neural signals into commands. But from an industrialization view, the algorithm is only the last layer. What decides whether a BCI reaches the clinic and the market is front-end hardware and system engineering.
For implantable BCI especially, the first barrier is the electrode: not just 'how many channels', but whether the signal stays stable after long-term implantation, whether impedance stays controlled, whether tissue reaction is acceptable, whether flexible materials reduce inflammation and scarring, and whether encapsulation resists fluids and corrosion for years. Next is the chip and wireless link, where high channel counts demand real-time acquisition, amplification, compression and transmission under power, heat and miniaturization constraints. Then comes packaging and system reliability: a BCI must run in body fluids, in motion, under long-term implantation, and if the encapsulation fails, the whole system fails.
Regulators are folding it into a device-development framework
Regulation is shifting too: in its guidance on implantable BCI, the FDA already places these products inside a clear medical-device development framework, focusing on non-clinical testing, IDE feasibility studies and pivotal trial design. Implantable BCI is no longer a research demo, but enters systematic validation of safety, reliability, effectiveness and a registration path, which raises the bar for material and packaging reliability.
The BIO angle
FAQ
Which BCI rounds closed in May 2026?
Per public reports: Ruiyi Xulian closed a ~RMB 100M Pre-A, Naosi Technology a >US$10M angel series, Nanoloop a tens-of-millions seed+ round, and Nuanxinjia RMB 300M strategic, spanning invasive, non-invasive and brain-spine routes.
Why say competition moved to system engineering?
The algorithm is only the last layer; durable implantation depends on the electrode, chip, encapsulation and stimulation working together. Fail any one and the system fails, which is why capital is betting on hardware and packaging.
What does this mean for material suppliers?
Electrode insulation, device encapsulation and tissue interfaces need long-term-implantable, biocompatible flexible materials, raising expectations for long-term stability, traceability and documentation of materials like medical silicone.
Related reading
- BCI in 2026: Technology Paths, Global Landscape and China's Rise | BIO Insights
- Brain–Spine Interfaces Heat Up: a 'Neural Bridge' Route and a $40M+ Angel Round | BIO Insights
- Map of China's Core BCI Companies: Three Tiers and Technology Routes | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.